News Novartis facing Gilenya generics again as Supreme Court lift... Novartis' hopes that the Supreme Court would protect its big-selling multiple sclerosis drug Gilenya from generic competition have been dashed.
Views & Analysis Increasing access to medicines: A critical look at pharmaceu... Extending patents is restricting patients’ access to the treatments they need.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends